Skip to main content

Traws Pharma, Inc.

corporate_fare Company Profile

Traws Pharma, Inc.

TRAW·NASDAQ·Life Sciences·CIK 0001130598

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing new treatments for respiratory viral diseases. The company is advancing investigational antiviral agents designed to be potent against difficult-to-treat or resistant virus strains, with an emphasis on safety and simple dosing. On April 1, 2024, Traws Pharma, then known as Onconova Therapeutics, Inc., merged with Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company. Before the merger, the company's business focused on discovering and developing cancer treatments. After the merger, the business expanded to include developing therapies for respiratory viral diseases. Following the merger, Traws Pharma has four clinical programs. These include tivoxavir marboxil, an investigational oral, small molecule CAP-dependent endonuclease inhibitor intended as a single-dose treatment for bird flu and seasonal influenza. Tivoxavir marboxil works by inhibiting the cap-dependent endonuclease (CEN) enzyme, which is crucial for influenza virus replication, thereby impeding replication of influenza A or B and bird flu viral strains. Another program is ratutrelvir, an inhibitor of the main protease (3CL protease) of the SAR-CoV-2 virus, which causes COVID-19. The company also continues to develop narazaciclib (ON 123300), a multi-targeted kinase inhibitor for solid tumors and hematological malignancies, used alone or with other anti-cancer therapies, and rigosertib, investigated alone or in combination for various cancers.

Traws Pharma, Inc. (NASDAQ:TRAW) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for TRAW at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for TRAW spans 10-Q, 8-K, S-1, DEF 14A.

Recent high-impact activity:

  • Traws 10-Q: $2.3M Cash, Going Concern Doubt, 35.5M Warrant Overhang
  • Traws Pharma Posts Q3 Loss, $2.3M Cash; TXM Resubmission Set for Q4
  • Traws Reports Final Phase 2a Ratutrelvir Data, Plans FDA Talks on PAXLOVID-Ineligible Path
  • Traws Registers Resale of 135.1M Shares Behind $50M Roth Equity Line
  • Traws Pharma Signs $50M Equity Line With Roth Principal Investments

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.79M
Net Income
$9.17M
Diluted EPS
$0.82
Op. Cash Flow
-$18.18M
Free Cash Flow
-$20.77M
Operating Income
-$17.88M
Cash & Equivalents
$3.82M
Debt / Equity
0.00×
Net Margin
328.7%
Shares Outstanding
9.07M sh
Source: 10-K · filed 2026-04-30 · accession 0001104659-26-053041

Short Interest & Short Volume

4.14 days to cover

FINRA reported short interest of 683,674 shares in TRAW as of the October 30, 2026 settlement, a 0.3% decrease from the prior period — about 4.1 days to cover at its recent average daily volume. On November 20, 2026, 46.0% of TRAW volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)683,674 shares as of October 30, 2026
Change vs prior period▼ 0.3%
Days to cover4.14 at avg daily volume of 165,069
Daily short volume (FINRA facilities)46.0% of 148,017 shares on November 20, 2026
5-day average short volume49.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for TRAW, detected from its recent SEC filings · based on capital-structure filings through 2026-10-26.

1 recent capital raiseATM program2 shelf registrations

ATM Program Launched · Dilution Impact

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$0.165 -5.71% today
52-week range · as of 2026-11-16 $0.165 – $3.23
Market cap
$2.69M
Volume
382K (2.0× avg)
3-mo avg 187K
Live data · 2026-11-21 10:29 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TRAW - Latest Insights

TRAW
Nov 16, 2026, 4:58 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.240
Real-time Price: $0.165 info
Change: -$0.075 (-31%) info
Market Cap: $2.689M info
TRAW
Nov 16, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.240
Real-time Price: $0.165 info
Change: -$0.075 (-31%) info
Market Cap: $2.689M info
TRAW
Nov 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.252
Real-time Price: $0.165 info
Change: -$0.087 (-35%) info
Market Cap: $2.689M info
TRAW
Oct 26, 2026, 4:47 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.350
Real-time Price: $0.165 info
Change: -$0.185 (-53%) info
Market Cap: $2.689M info
TRAW
Oct 23, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3425
Real-time Price: $0.165 info
Change: -$0.1775 (-52%) info
Market Cap: $2.689M info
TRAW
Oct 20, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3767
Real-time Price: $0.165 info
Change: -$0.2117 (-56%) info
Market Cap: $2.689M info
TRAW
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4803
Real-time Price: $0.165 info
Change: -$0.3153 (-66%) info
Market Cap: $2.689M info
TRAW
Aug 14, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.571
Real-time Price: $0.165 info
Change: -$0.406 (-71%) info
Market Cap: $2.689M info
TRAW
Aug 14, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.571
Real-time Price: $0.165 info
Change: -$0.406 (-71%) info
Market Cap: $2.689M info
TRAW
Jul 31, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.450
Real-time Price: $0.165 info
Change: -$0.285 (-63%) info
Market Cap: $2.689M info
TRAW
Jul 10, 2026, 4:01 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $0.760
Real-time Price: $0.165 info
Change: -$0.595 (-78%) info
Market Cap: $2.689M info
TRAW
Jul 09, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6751
Real-time Price: $0.165 info
Change: -$0.5101 (-76%) info
Market Cap: $2.689M info
TRAW
Jun 22, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.846
Real-time Price: $0.165 info
Change: -$0.681 (-80%) info
Market Cap: $2.689M info
TRAW
Jun 12, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.165 info
Change: -$0.845 (-84%) info
Market Cap: $2.689M info
TRAW
May 29, 2026, 9:00 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.55
Real-time Price: $0.165 info
Change: -$1.38 (-89%) info
Market Cap: $2.689M info
TRAW
May 27, 2026, 8:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.64
Real-time Price: $0.165 info
Change: -$1.47 (-90%) info
Market Cap: $2.689M info
TRAW
May 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $0.165 info
Change: -$1.39 (-89%) info
Market Cap: $2.689M info
TRAW
May 22, 2026, 8:55 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.165 info
Change: -$1.31 (-89%) info
Market Cap: $2.689M info
TRAW
May 22, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.49
Real-time Price: $0.165 info
Change: -$1.33 (-89%) info
Market Cap: $2.689M info
TRAW
May 19, 2026, 4:01 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.59
Real-time Price: $0.165 info
Change: -$1.43 (-90%) info
Market Cap: $2.689M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets